ORBIMED ADVISORS LLC other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}

Adviser Profile

As of Date:

03/29/2023

Adviser Type:

- Large advisory firm


Number of Employees:

106 8.16%

of those in investment advisory functions:

79 8.22%


Registration:

SEC, Approved, 4/22/2002

AUM:

18,277,550,000 5.52%

of that, discretionary:

18,277,550,000 5.52%


SMA’s:

NO

Private Funds:

25

Websites (details):
Contact info

Phone: 212 xxxxxxx

Fax: 212 xxxxxxx

Client Types:

- Pooled investment vehicles

Advisory Activities:

- Portfolio management for pooled investment vehicles

Compensation Arrangments:

- A percentage of assets under your management
- Performance-based fees

Reported AUM

Discretionary
Non-discretionary
21B 18B 15B 12B 9B 6B 3B
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

OrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma Inc
11/15/2023

Related Stocks: KNTE, ISRG, SVA, BSX, THRX, ELVN,

gurufocus.com

Orbimed Advisors LLC Bolsters Portfolio with Alpine Immune Sciences Inc Stake
11/14/2023

Related Stocks: ALPN, ISRG, SVA, BSX, THRX, ELVN,

gurufocus.com

OrbiMed Advisors LLC Reduces Stake in NeuroPace Inc
10/05/2023

Related Stocks: NPCE, ISRG, SVA, BSX, THRX, ELVN,

gurufocus.com

OrbiMed Advisors LLC Reduces Stake in Galecto Inc
08/17/2023

Related Stocks: GLTO, ISRG, SVA, BSX, THRX, ELVN,

gurufocus.com

OrbiMed Advisors LLC Reduces Stake in Gracell Biotechnologies Inc
08/12/2023

Related Stocks: GRCL, SVA, BMY, BSX, HUM, ELVN,

gurufocus.com

OrbiMed Advisors LLC Reduces Stake in Galecto Inc
08/03/2023

Related Stocks: GLTO, SVA, BMY, BSX, HUM, ELVN,

gurufocus.com


Private Funds Structure

Fund Type Count GAV
Hedge Fund 7 $2,277,072,000
Private Equity Fund 3 $2,945,579,000
Other Private Fund 15 $10,129,093,000

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund AUM # funds
SONA ASSET MANAGEMENT (US) LLC 6.4b - - - - - - - -
CATTERTON MANAGEMENT COMPANY, L.L.C. 21b - - - - - 8.4b - -
HIGHBRIDGE CAPITAL MANAGEMENT, LLC 10.1b - - - - - - - -
CENTURY PARK CAPITAL PARTNERS, LLC - - 239.5m - - - - - -
TITAN ADVISORS, LLC 1.7b - 218.7m - - - - - -
WHITE OAK GLOBAL ADVISORS, LLC 1.8b - 4.2b - - - - - -
PARSIFAL CAPITAL MANAGEMENT, LP 1.9b - - - - - - - -
GROSVENOR CAPITAL MANAGEMENT, L.P. 32b - 1.3b - - - - - -
BENCHMARK PLUS MANAGEMENT, LLC 1b - - - - - - - -
CAMBRIAN ASSET MANAGEMENT, INC. 204.7m - - - - - - - -

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
P8696W104 SINOVAC BIOTECH LTD $340,000,000 7.00% 0.00% 0.00%
101137107 BOSTON SCIENTIFIC CORP $174,599,040 4.00% -4.00% -2.00%
444859102 HUMANA INC $166,633,100 4.00% 7.00% -2.00%
29337E102 ENLIVEN THERAPEUTICS INC $122,917,297 3.00%
46120E602 INTUITIVE SURGICAL INC $145,852,710 3.00% -31.00% -20.00%
09062X103 BIOGEN INC $143,103,168 3.00%
09061G101 BIOMARIN PHARMACEUTICAL INC $142,913,781 3.00%
071813109 BAXTER INTL INC $84,533,826 2.00%
22663K107 CRINETICS PHARMACEUTICALS IN $86,129,241 2.00%
254604101 DISC MEDICINE INC $106,627,546 2.00% 6.00% 0.00%

Brochure Summary

Overview

OrbiMed is an investment manager focused exclusively on the healthcare sector. OrbiMed’s predecessor was founded in 1989, and OrbiMed is owned by Sven H. Borho, Carl L. Gordon, Jonathan T. Silverstein, W. Carter Neild, Geoffrey C. Hsu, C. Scotland Stevens, and David P. Bonita. As of December 31, 2018 OrbiMed, together with its affiliates and relying advisers, managed approximately $11.4 billion on a discretionary basis on behalf of 23 clients. OrbiMed provides discretionary investment management services to U.S. and non-U.S. public and private funds. In providing such services, OrbiMed utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device,
healthcare services and other companies in the global healthcare sector. Such strategies generally include, within the healthcare sector and subject to the investment program of each client, investments in the securities of U.S. and non-U.S. public and/or private companies. Clients are permitted to set guidelines for their accounts which customize OrbiMed’s core strategies, including restrictions related to sub-sector, geographic and other weightings. In providing its investment advisory services, OrbiMed determines when and which investments will be acquired, disposed of, or exchanged on behalf of its clients to maintain a portfolio consistent with each client’s objectives.